JOHN IMIG

Summary

Affiliation: Medical College of Wisconsin
Country: USA

Publications

  1. pmc Orally active epoxyeicosatrienoic acid analog attenuates kidney injury in hypertensive Dahl salt-sensitive rat
    Md Abdul Hye Khan
    Medical College of Wisconsin, 8701 Watertown Plank Rd, Milwaukee, WI 53226
    Hypertension 62:905-13. 2013
  2. pmc Novel orally active epoxyeicosatrienoic acid (EET) analogs attenuate cisplatin nephrotoxicity
    Md Abdul Hye Khan
    Department of Pharmacology and Toxicology, Medical College of Wisconsin, 8701 Watertown Plank Rd, Milwaukee, Wisconsin 53226, USA
    FASEB J 27:2946-56. 2013
  3. pmc Immune and inflammatory role in renal disease
    John D Imig
    Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
    Compr Physiol 3:957-76. 2013
  4. pmc Epoxyeicosatrienoic acids, 20-hydroxyeicosatetraenoic acid, and renal microvascular function
    John D Imig
    Department of Pharmacology and Toxicology, Cardiovascular Research Center, Medical College of Wisconsin, Milwaukee, WI 53226, USA
    Prostaglandins Other Lipid Mediat 104:2-7. 2013
  5. pmc Soluble epoxide hydrolase inhibition and peroxisome proliferator activated receptor γ agonist improve vascular function and decrease renal injury in hypertensive obese rats
    John D Imig
    Department of Pharmacology and Toxicology and Cardiovascular Research Center, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA
    Exp Biol Med (Maywood) 237:1402-12. 2012
  6. pmc Development of epoxyeicosatrienoic acid analogs with in vivo anti-hypertensive actions
    John D Imig
    Department of Pharmacology and Toxicology, Medical College of Wisconsin Milwaukee, WI, USA
    Front Physiol 1:157. 2010
  7. pmc Epoxides and soluble epoxide hydrolase in cardiovascular physiology
    John D Imig
    Department of Pharmacology and Toxicology, Cardiovascular Research Center, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
    Physiol Rev 92:101-30. 2012
  8. pmc Cytochrome P450 eicosanoids and cerebral vascular function
    John D Imig
    Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI 53226, USA
    Expert Rev Mol Med 13:e7. 2011
  9. pmc Targeting epoxides for organ damage in hypertension
    John D Imig
    Department of Pharmacology and Toxicology, Cardiovascular Research Center, Medical College of Wisconsin, Milwaukee, WI 53226, USA
    J Cardiovasc Pharmacol 56:329-35. 2010
  10. pmc Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases
    John D Imig
    Department of Pharmacology and Toxicology, Cardiovascular Research Center, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, Wisconsin 53226, USA
    Nat Rev Drug Discov 8:794-805. 2009

Collaborators

Detail Information

Publications14

  1. pmc Orally active epoxyeicosatrienoic acid analog attenuates kidney injury in hypertensive Dahl salt-sensitive rat
    Md Abdul Hye Khan
    Medical College of Wisconsin, 8701 Watertown Plank Rd, Milwaukee, WI 53226
    Hypertension 62:905-13. 2013
    ....
  2. pmc Novel orally active epoxyeicosatrienoic acid (EET) analogs attenuate cisplatin nephrotoxicity
    Md Abdul Hye Khan
    Department of Pharmacology and Toxicology, Medical College of Wisconsin, 8701 Watertown Plank Rd, Milwaukee, Wisconsin 53226, USA
    FASEB J 27:2946-56. 2013
    ..Collectively, our data provide evidence that EET analogs attenuate cisplatin-induced nephrotoxicity by reducing oxidative stress, inflammation, ER stress, and apoptosis without affecting the chemotherapeutic effects of cisplatin...
  3. pmc Immune and inflammatory role in renal disease
    John D Imig
    Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
    Compr Physiol 3:957-76. 2013
    ..An overview of common forms of acute and chronic renal disease is provided, followed by a discussion of common therapies that have anti-inflammatory or immunosuppressive effects in the treatment of renal disease...
  4. pmc Epoxyeicosatrienoic acids, 20-hydroxyeicosatetraenoic acid, and renal microvascular function
    John D Imig
    Department of Pharmacology and Toxicology, Cardiovascular Research Center, Medical College of Wisconsin, Milwaukee, WI 53226, USA
    Prostaglandins Other Lipid Mediat 104:2-7. 2013
    ..These findings have demonstrated the important contributions that 20-HETE and EETs play in the regulation of renal microvascular function. ..
  5. pmc Soluble epoxide hydrolase inhibition and peroxisome proliferator activated receptor γ agonist improve vascular function and decrease renal injury in hypertensive obese rats
    John D Imig
    Department of Pharmacology and Toxicology and Cardiovascular Research Center, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA
    Exp Biol Med (Maywood) 237:1402-12. 2012
    ..These results indicate that even though sEHi or PPARγ agonist have benefits when used individually, the combination is more beneficial for the multidisease features in cardiometabolic syndrome...
  6. pmc Development of epoxyeicosatrienoic acid analogs with in vivo anti-hypertensive actions
    John D Imig
    Department of Pharmacology and Toxicology, Medical College of Wisconsin Milwaukee, WI, USA
    Front Physiol 1:157. 2010
    ....
  7. pmc Epoxides and soluble epoxide hydrolase in cardiovascular physiology
    John D Imig
    Department of Pharmacology and Toxicology, Cardiovascular Research Center, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
    Physiol Rev 92:101-30. 2012
    ..Given the impact of EETs to cardiovascular physiology, there is emerging evidence that development of EET-based therapeutics will be beneficial for cardiovascular diseases...
  8. pmc Cytochrome P450 eicosanoids and cerebral vascular function
    John D Imig
    Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI 53226, USA
    Expert Rev Mol Med 13:e7. 2011
    ..Thus, the CYP eicosanoids are key regulators of cerebral vascular function and novel therapeutic targets for cardiovascular diseases and neurological disorders...
  9. pmc Targeting epoxides for organ damage in hypertension
    John D Imig
    Department of Pharmacology and Toxicology, Cardiovascular Research Center, Medical College of Wisconsin, Milwaukee, WI 53226, USA
    J Cardiovasc Pharmacol 56:329-35. 2010
    ..These experimental findings provide evidence for sEH inhibitors and EET agonists as a therapeutic approach for cardiovascular diseases, hypertension, and the associated end-organ damage...
  10. pmc Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases
    John D Imig
    Department of Pharmacology and Toxicology, Cardiovascular Research Center, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, Wisconsin 53226, USA
    Nat Rev Drug Discov 8:794-805. 2009
    ....
  11. pmc Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection
    Alexis N Simpkins
    Department of Pharmacology and Toxicology, Medical College of Wisconsin, 8701 Watertown Plank Rd, Milwaukee, WI 53226, USA
    Am J Pathol 174:2086-95. 2009
    ....
  12. pmc Epoxyeicosatrienoic acid analogs and vascular function
    V Sudhahar
    Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, 53226, USA
    Curr Med Chem 17:1181-90. 2010
    ..Overall, this review will highlight the important knowledge garnered by the development of EET analogs and their possible value in the treatment of cardiovascular diseases...
  13. pmc Simvastatin and tempol protect against endothelial dysfunction and renal injury in a model of obesity and hypertension
    Sarah F Knight
    Vascular Biology Center, Medical College of Georgia, Augusta, Georgia, USA
    Am J Physiol Renal Physiol 298:F86-94. 2010
    ..These data indicate that tempol and simvastatin treatment via a reduction in oxidative stress improve renal endothelial function and decrease glomerular injury in a model of obesity and hypertension...

Research Grants12

  1. OXYGENASE METABOLITES AND RENAL VASCULAR ACTIVITY
    JOHN IMIG; Fiscal Year: 1999
    ..Results of these studies will further define the renin-angiotensin system and determine the role of arachidonic acid metabolism in the development of angiotensin-dependent hypertension. ..
  2. Epoxyeicosanoids and Renal Vascular Function in Obesity & Hypertension
    John D Imig; Fiscal Year: 2010
    ..On the whole, the proposed experiments in this application will provide novel insight and therapeutic targets for the treatment of chronic kidney disease in obesity and hypertension. ..
  3. Epoxyeicosanoids and Renal Vascular Function in Obesity & Hypertension
    JOHN IMIG; Fiscal Year: 2009
    ..On the whole, the proposed experiments in this application will provide novel insight and therapeutic targets for the treatment of chronic kidney disease in obesity and hypertension. ..
  4. Oxygenase Metabolites and Renal Microvascular Reactivity
    JOHN IMIG; Fiscal Year: 2005
    ..Collectively, these studies will provide a comprehensive understanding of epoxide hydrolases in the long-term regulation of blood pressure and renal hemodynamic function during angiotensin II hypertension. ..
  5. Oxygenase Metabolites and Renal Microvascular Reactivity
    JOHN IMIG; Fiscal Year: 2004
    ..Collectively, these studies will provide a comprehensive understanding of epoxide hydrolases in the long-term regulation of blood pressure and renal hemodynamic function during angiotensin II hypertension. ..
  6. Oxygenase Metabolites and Renal Microvascular Reactivity
    JOHN IMIG; Fiscal Year: 2003
    ..Collectively, these studies will provide a comprehensive understanding of epoxide hydrolases in the long-term regulation of blood pressure and renal hemodynamic function during angiotensin II hypertension. ..
  7. Oxygenase Metabolites and Renal Microvascular Reactivity
    JOHN IMIG; Fiscal Year: 2002
    ..Collectively, these studies will provide a comprehensive understanding of epoxide hydrolases in the long-term regulation of blood pressure and renal hemodynamic function during angiotensin II hypertension. ..
  8. OXYGENASE METABOLITES AND RENAL VASCULAR ACTIVITY
    JOHN IMIG; Fiscal Year: 2001
    ..Results of these studies will further define the renin-angiotensin system and determine the role of arachidonic acid metabolism in the development of angiotensin-dependent hypertension. ..
  9. OXYGENASE METABOLITES AND RENAL VASCULAR ACTIVITY
    JOHN IMIG; Fiscal Year: 2001
    ..Results of these studies will further define the renin-angiotensin system and determine the role of arachidonic acid metabolism in the development of angiotensin-dependent hypertension. ..
  10. OXYGENASE METABOLITES AND RENAL VASCULAR ACTIVITY
    JOHN IMIG; Fiscal Year: 2000
    ..Results of these studies will further define the renin-angiotensin system and determine the role of arachidonic acid metabolism in the development of angiotensin-dependent hypertension. ..
  11. Epoxyeicosanoids and Renal Vascular Function in Obesity & Hypertension
    JOHN IMIG; Fiscal Year: 2009
    ..On the whole, the proposed experiments in this application will provide novel insight and therapeutic targets for the treatment of chronic kidney disease in obesity and hypertension. ..